Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 5/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.52 |
| ▸ | ITGAL | P20701 | 1/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9653545 | 0.92 | ECE1 (0.62) | ECE1ERAP2GHSRACEITGB2 | |
| SCHEMBL2181464 | 0.92 | ECE1 (0.62) | ECE1ERAP2GHSRACEITGB2 | |
| SCHEMBL30052048 | 0.92 | ITGB2 (0.58) | ERAP2GHSRACEITGB2ICAM1 | |
| SCHEMBL29705214 | 0.90 | GHSR (0.54) | ECE1ERAP2GHSR | |
| SCHEMBL30398128 | 0.90 | GHSR (0.55) | ECE1GHSRACEITGB2ICAM1 | |
| SCHEMBL30052260 | 0.88 | GHSR (0.62) | ECE1ERAP2GHSRACEITGB2 | |
| SCHEMBL31606505 | 0.86 | GHSR (0.65) | ECE1ERAP2GHSRACEITGB2 | |
| SCHEMBL31442126 | 0.85 | GHSR (0.54) | ERAP2GHSRIL1RNERAP1 | |
| SCHEMBL30736101 | 0.85 | MMP2 (0.60) | ECE1GHSR | |
| SCHEMBL29533411 | 0.85 | GHSR (0.65) | ECE1GHSRACEITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | ECE1 2106/4885ERAP2 3266/4885GHSR 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.